Havah Therapeutics Files Patent for HAV-088 in Breast Cancer Treatment Havah Therapeutics, a clinical-stage biopharmaceutical company focused on developing innovative therapies for the prevention and treatment of breast cancer, has announced the filing of a new provisional patent application for…
Alcon Acquires Majority Stake in Aurion Biotech to Advance Corneal Cell Therapy Alcon, a global leader in eye care, has announced the acquisition of a majority interest in Aurion Biotech, Inc., a clinical-stage company specializing in advanced cell therapies for…
Epicrispr Biotech Raises $68M for FSHD Epigenetic Therapy Trial Epicrispr Biotechnologies, a pioneering biotechnology company dedicated to developing curative therapies, has announced the successful first close of its Series B financing, securing $68 million. The funds will be used to…
RenovoRx TAMP™ Pre-Clinical Results to Be Awarded at SIR 2025 RenovoRx, Inc. (“RenovoRx” or the “Company”), a pioneering life sciences company dedicated to advancing targeted oncology therapies, is pleased to announce that its research supporting the Company’s proprietary Trans-Arterial Micro-Perfusion…
Merck Licenses HRS-5346 for Cardiovascular Disease from Hengrui Merck, known as MSD outside of the United States and Canada, and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui Pharma”), a leading global pharmaceutical company with a strong focus on scientific and technological…
Xcell Biosciences Partners with Planet Innovation and Royal Perth Hospital to Advance Cell Therapy Manufacturing Xcell Biosciences Australia Pty Ltd (Xcellbio), a subsidiary of the San Francisco-based biotechnology company specializing in instrumentation for cell and gene therapy applications, has announced…
Veracyte’s Whole-Genome Sequencing-Based MRD Test Shows High Accuracy for Muscle-Invasive Bladder Cancer Detection Veracyte, Inc., a leader in cancer diagnostics, has announced groundbreaking new data demonstrating the accuracy and effectiveness of its whole-genome sequencing (WGS)-based minimal residual disease (MRD) testing…
Dr. Mike Graham Named Head of R&D at Bayer Crop Science Bayer has officially announced that Dr. Mike Graham will assume the role of Head of Research & Development (R&D) for Bayer’s Crop Science division. In this capacity, he will…
CEL-SCI: Multikine Boosts Quality of Life by Up to 95% in Head & Neck Cancer Patients CEL-SCI Corporation (NYSE American: CVM) has recently announced the publication of new data from its Phase 3 study of Multikine* (Leukocyte Interleukin, Injection) in…
Neurogene Announces Q4 & Full-Year 2024 Results, Updates Neurogene Inc., a clinical-stage company dedicated to developing life-changing genetic medicines for patients and families affected by rare neurological diseases, has announced its fourth quarter and full-year 2024 financial results along with…
Pearsanta Acquires Adductomics Tech for Cancer Risk Monitoring Aditxt, Inc. (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, has announced that its subsidiary, Pearsanta, Inc. (“Pearsanta”), has completed the acquisition of key patents related to adductomics-based…
DNAnexus & AlidaBio Partner to Advance RNA Analysis DNAnexus, Inc., a leading provider of enterprise platforms for precision health data, has announced a strategic collaboration with Alida Biosciences (AlidaBio), a pioneer in RNA epigenomic research tools. This partnership aims to…